Modality
Fusion Protein
MOA
EGFRi
Target
TIGIT
Pathway
Cell Cycle
CRCPsoriasis
Development Pipeline
Preclinical
~Apr 2020
→ ~Jul 2021
Phase 1
Oct 2021
→ Aug 2029
Phase 1Current
NCT06973572
415 pts·Psoriasis
2022-06→TBD·Completed
NCT05813221
1,380 pts·CRC
2021-10→2029-08·Active
1,795 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-08-093.4y awayInterim· CRC
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1
Active
P1
Complet…
Catalysts
Interim
2029-08-09 · 3.4y away
CRC
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06973572 | Phase 1 | Psoriasis | Completed | 415 | SRI-4 |
| NCT05813221 | Phase 1 | CRC | Active | 1380 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| Miritinib | Neurocrine | Phase 3 | TIGIT |